- Tel Aviv University scientists have isolated two antibodies that neutralize all known strains of – including Omicron – with up to 95% efficiency.
- The researchers: Targeted treatment with antibodies and their delivery to the body in high concentrations may serve as an effective substitute for vaccines, especially for at-risk populations such as those with weakened immune systems. By using antibody treatment, it is possible that the need to provide repeated booster shots to the entire population every time a new variant emerges will be eliminated.
A scientific breakthrough against COVID-19 has been realized by Tel Aviv University. A team of scientists from the university has demonstrated that antibodies isolated from the immune system of recovered COVID-19 patients are effective in neutralizing all known strains of the virus. This includes the Delta and the Omicron variants. This discovery may eliminate the need for repeated booster vaccinations and strengthen the immune system of populations at risk, according to the researchers.
Dr. Natalia Freund and doctoral students Michael Mor and Ruofan Lee of the Department of Clinical Microbiology and Immunology at the Sackler Faculty of Medicine led the research. The study was conducted in collaboration with Dr. Ben Croker of the University of California San Diego (UCSD). Prof. Ye Xiang of Tsinghua University in Beijing as well as Prof. Meital Gal-Tanamy and Dr. Moshe Dessau of Bar-Ilan University also took part in the study. The study was published on August 5 in the Nature journal Communications Biology.
“…we showed that the various antibodies that are formed in response to infection with the original virus are directed against different sites of the virus.”
The current study is a continuation of a preliminary study that was conducted in October 2020, at the height of the COVID-19 crisis. At that time, Dr. Freund and her colleagues sequenced all the B immune system cells from the blood of people in Israel who had recovered from the original COVID strain. They isolated nine antibodies that the patients produced. The scientists have now found that some of these antibodies are exceptionally effective in neutralizing the new coronavirus variants, Delta and Omicron.
Dr. Freund: “In the previous study, we showed that the various antibodies that are formed in response to infection with the original virus are directed against different sites of the virus. The most effective antibodies were those that bound to the virus’s ‘spike’ protein, in the same place where the spike binds to the cellular receptor ACE2. Of course, we were not the only ones to isolate these antibodies, and the global health system made extensive use of them until the arrival of the different variants of the coronavirus, which in fact rendered most of those antibodies useless.
“In the current study, we proved that two other antibodies, TAU-1109 and TAU-2310, which bind the viral spike protein in a different area from the region where most of the antibodies were concentrated until now (and were, therefore, less effective in neutralizing the original strain) are actually very effective in neutralizing the Delta and Omicron variants. According to our findings, the effectiveness of the first antibody, TAU-1109, in neutralizing the Omicron strain is 92%, and in neutralizing the Delta strain, 90%. The second antibody, TAU-2310, neutralizes the Omicron variant with an efficacy of 84%, and the Delta variant with an efficacy of 97%.”
Dr. Freund believes that the surprising effectiveness of these antibodies might be related to the evolution of the virus.
“The infectivity of the virus increased with each variant because each time, it changed the amino following vaccinations. In contrast, the antibodies TAU-1109 and TAU-2310 don’t bind to the ACE2 receptor binding site, but to another region of the spike protein – an area of the viral spike that for some reason does not undergo many mutations – and they are therefore effective in neutralizing more viral variants. These findings emerged as we tested all the known COVID strains to date.”sequence of the part of the spike protein that binds to the ACE2 receptor, thereby increasing its infectivity and at the same time evading the natural antibodies that were created
The two antibodies, cloned in Dr. Freund’s laboratory at Tel Aviv University, were sent for tests to check their effectiveness against live viruses in laboratory cultures at the University of California San Diego (UCSD). They were also tested against pseudoviruses in the laboratories of the Faculty of Medicine of Bar-Ilan University in the Galilee. In both tests, the results were identical and equally encouraging.
These antibodies can bring about a real revolution in the fight against COVID-19 according to Dr. Freund.
“We need to look at the COVID-19 pandemic in the context of previous disease outbreaks that humankind has witnessed. People who were vaccinated against smallpox at birth and who today are 50 years old still have antibodies, so they are probably protected, at least partially, from the monkeypox virus that we have recently been hearing about.
“Unfortunately, this is not the case with the coronavirus. For reasons we still don’t yet fully understand, the level of antibodies against COVID-19 declines significantly after three months, which is why we see people getting infected again and again, even after being vaccinated three times.
“In our view, targeted treatment with antibodies and their delivery to the body in high concentrations can serve as an effective substitute for repeated boosters, especially for at-risk populations and those with weakened immune systems. COVID-19 infection can cause serious illness, and we know that providing antibodies in the first days following infection can stop the spread of the virus. It is, therefore, possible that by using effective antibody treatment, we will not have to provide booster doses to the entire population every time there is a new variant.”
What are your thoughts on this article?
Let us know in the comments below!
What topics should we cover next?
Email us your ideas at email@example.com!
Did you know we have different groups for different conditions?